CRISPR Used to Identify Cancer Immunotherapy Targets

Sophia Ktori, GEN News Highlights, 08 August 2017,

One of CRISPR’s most promising therapeutic uses is in the creation of cancer immunotherapies.  Scientists at the National Institute of Health, working in close collaboration with Feng Zhang of the Broad Institute, developed a CRISPR/Cas9 screen allowing them to test many genes for their effect on T-cell responses.  The results, published in Nature (, identified 100 genes that, upon mutating, impacted resistance to T-cell attack.  This report provides a potential explanation as to why some patients do not demonstrate positive response to immunotherapy treatments and underscores the potential benefits of individualized medicine.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply